Table 1. Patient characteristics... | American Society of Hematology

Table 1.

Patient characteristics

Patients UPN	Age/sex	Year of diagnosis	PNH cells %		Immunosuppressive treatment
Patients UPN	Age/sex	Year of diagnosis	Granulocytes	RBC type III/II^*	Immunosuppressive treatment
MSK1	46/M	1994	100	71	None
MSK7	24/F	1993	80	45/15	ATG^†1993
MSK11	37/M	1985	93	88/4	ATG 1985, 1995
					Cyclosporine 1995-99
MSK12	34/M	1986	92	62	None
MSK14	45/F	1995	82	60	None
MSK17	40/M	1995	59	64	Steroids
MSK21	29/M	1996	50	21	ATG 1996
MSK22	26/M	1996	92	61	None
MSK24	29/F	1995	85	14/3	None
MSK27	35/F	1996	40	8/15	None
MSK28	38/F	1997	49	12/5	None
MSK32	16/F	1995	63	9/46	ATG 1995
MSK35	30/M	1996	90	67	ALG 1998
MSK42	47/F	1982	80	7/3	Cyclophosphamide 1999
MSK46	48/F	1998	60	0/20	Fludarabine 1998
MSK47	32/F	1999	90	55/4	None
HH8	27/F	1989	23	36	None
HH22	45/F	1991	77	18	None
HH54	45/M	1994	85	23	None

Patients UPN	Age/sex	Year of diagnosis	PNH cells %		Immunosuppressive treatment
Patients UPN	Age/sex	Year of diagnosis	Granulocytes	RBC type III/II^*	Immunosuppressive treatment
MSK1	46/M	1994	100	71	None
MSK7	24/F	1993	80	45/15	ATG^†1993
MSK11	37/M	1985	93	88/4	ATG 1985, 1995
					Cyclosporine 1995-99
MSK12	34/M	1986	92	62	None
MSK14	45/F	1995	82	60	None
MSK17	40/M	1995	59	64	Steroids
MSK21	29/M	1996	50	21	ATG 1996
MSK22	26/M	1996	92	61	None
MSK24	29/F	1995	85	14/3	None
MSK27	35/F	1996	40	8/15	None
MSK28	38/F	1997	49	12/5	None
MSK32	16/F	1995	63	9/46	ATG 1995
MSK35	30/M	1996	90	67	ALG 1998
MSK42	47/F	1982	80	7/3	Cyclophosphamide 1999
MSK46	48/F	1998	60	0/20	Fludarabine 1998
MSK47	32/F	1999	90	55/4	None
HH8	27/F	1989	23	36	None
HH22	45/F	1991	77	18	None
HH54	45/M	1994	85	23	None

Red blood cells (RBCs) with complete (type III) or partial (type II) loss of cell surface expression of GPI-linked proteins.

Antithymocyte globulin.